Introduction
Bleeding is a frequent complication of the management of patients with coronary artery disease (CAD), especially those presenting with acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI), and of patients with atrial fibrillation (AF). Randomized trials have shown a risk of major bleeding of 1-8% at 30 days in ACS patients, [1] [2] [3] [4] [5] and of 2-5% per year in patients with AF treated with oral anticoagulants (OACs). 6 Observational studies suggest that bleeding risk is even higher. 7 Major bleeding is associated with a subsequent increase in both short-and long-term mortality. [7] [8] [9] [10] [11] [12] [13] Even minimal bleeding may have prognostic importance because it frequently leads to disruption of antithrombotic therapy. 14, 15 Several mechanisms have been put forward to explain the relationship between major bleeding and increased mortality ( Figure 1) . The overlap in risk factors for bleeding and ischaemic events means that patients who are more likely to suffer from bleeding complications of antithrombotic therapy also tend to be at higher risk of thrombotic events. 16 Discontinuation of antithrombotic drugs may lead to an increased rate of thrombotic events due to the progressive recovery of platelet function and coagulation activity. [17] [18] [19] In addition, bleeding may provoke prothrombotic responses beyond those related to discontinuation of antithrombotic drugs. 20, 21 Clearly, balancing the risks of further bleeding vs. potentially fatal thrombotic events is critical for decisions about if and when to restart antithrombotic therapy after bleeding.
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. 
Aim of consensus document
Although several recommendations have been published dealing with the acute management of bleeding in patients treated with antithrombotic drugs, [22] [23] [24] there is an unmet need for guidance on how to manage antithrombotic therapy after bleeding has occurred. Patients with recent bleeding have been excluded from most randomized trials of antithrombotic therapy and rigorous evidence to inform decisions is scarce. While waiting for observational and randomized data to accrue, this consensus paper offers a European perspective on managing antithrombotic therapy after bleeding in patients with CAD and/or AF, including which drugs to stop, which to restart, and when. For the purpose of this document, major bleeding has been defined according to the Bleeding Academic Research Consortium (BARC) 25 as BARC type 3, minor bleeding as BARC type 2 and minimal as BARC type 1. Cessation of antithrombotic therapy has been defined according to Mehran et al. 19 as discontinuation (recommended, physician-directed withdrawal), interruption (temporary cessation of antiplatelet treatment due to surgical necessity with reinstitution within 14 days), or disruption (cessation of antiplatelet treatment due to bleeding or non-compliance).
Consensus definitions of thrombotic and haemorrhagic risks after bleeding Tables 1 and 2 present the authors' consensus definitions of thrombotic and haemorrhagic risks for CAD and AF patients who develop a bleeding event. Risks are stratified into five categories: low, low-to-moderate, moderate, high, and very high. Definitions are based on simple clinical parameters and validated scores. 26, 27 Although the value of platelet function testing for predicting ischaemic and bleeding risks was recently demonstrated in a cohort of >20 000 patients, 28 personalized treatment based on platelet function and/or genetic testing cannot be recommended in routine clinical practice due to insufficient prospective data. 29, 30 Ongoing studies further investigate this issue (e.g. NCT01538446, NCT01959451).
Consensus on the general management of antithrombotic therapy after bleeding
The concomitance of very high thrombotic and very high haemorrhagic risks in a patient with bleeding poses the most difficult treatment decisions. Given the increased risk of thrombotic events after premature cessation of antithrombotic drugs, our consensus is to consider resumption of oral antithrombotic therapy in all situations where there is a clear indication, even in case of major bleeding, as long as the bleeding event is not a life-threatening intracranial or extracranial bleed. When the thrombotic risk is higher than the risk of recurrent bleeding (according to Tables 1 and 2) , we suggest continuing antithrombotic therapy. When thrombotic risk is in equipoise with bleeding risk, we suggest only brief or temporary interruption of antithrombotic therapy. When bleeding risk outweighs thrombotic risk, we suggest considering, on a case to case basis, reducing the number and/or dose of antithrombotic drug(s). Whenever possible we strongly suggest recruiting patients into randomized trials or registries designed to address the many dilemmas discussed below. When this is not possible, we suggest applying the guidance provided by this consensus paper.
Antiplatelet therapy after extracranial bleeding
Patients with a recent acute coronary syndrome and/or percutaneous coronary intervention (<12 months)
The risk for new cardiovascular events is increased in patients with a recent ACS, especially during the first 3 months, and remains elevated up to 1 year after the acute event. 31 The importance of dual antiplatelet treatment (DAPT) with aspirin and a P2Y 12 inhibitor up to 1 year for these patients is well established. 32 After bleeding, no randomized trials have assessed whether stopping or restarting one or both antiplatelet agents is the best choice. In patients with a recently implanted coronary stent, premature disruption of one or both antiplatelet agents (especially the P2Y 12 inhibitor) has been shown to be the strongest predictor of stent thrombosis. [33] [34] [35] The risk of stent thrombosis increases with longer time off treatment, particularly more than 5 days, and if treatment is stopped within the 1st month after the procedure. 33, 34, 36, 37 One-year mortality rates for stent thrombosis remain as high as 10-14%. 38, 39 In a contemporary registry of over 5000 patients treated with PCI, cardiovascular risk was significantly increased when DAPT cessation was due to noncompliance or bleeding. 19 The risk was highest for the first 7 days after the start of disruption, but still high within 30 days. 19 Thus, it is important for clinicians to clearly appreciate the heightened risk of ischaemic events following premature cessation of antiplatelet therapy in patients with coronary stents. No reversible factor identified. HAS-BLED 3-4 Cessation of antithrombotic therapy discouraged because of very high thrombotic risk.
Moderate
Intracranial bleeding where cause of bleeding and relevant risk factors have been treated.
HAS-BLED ¼2
Extracranial major bleeding where the source has been identified and treated effectively. biolimus-coated stent may allow even shorter duration of DAPT (1  month) . 42 Therefore, decisions of whether and when to resume antiplatelet treatment after bleeding should also consider the type of stent(s). While the overall risk of stent thrombosis is lowest with the newest generation DES, the thrombotic risk appears higher with the new bioresorbable vascular scaffolds (BVS), owing to thrombogenicity related to strut thickness and extent of blood contact surface. 43, 44 Therefore, a longer DAPT duration and a more urgent need for resuming antiplatelet agents after bleeding may be needed with BVS, 45 although further studies specifically with this device are required to explore the optimal DAPT duration.
Patients on prasugrel, ticagrelor, or vorapaxar
In ACS patients treated with the newer P2Y 12 inhibitors prasugrel or ticagrelor, there are no data available for resumption after bleeding.
The risk of non-CABG related bleeding with these agents is significantly higher compared to clopidogrel. Although the evidence is weak, clopidogrel (which results in less platelet inhibition and a lower risk of spontaneous bleeding) may be used as P2Y 12 inhibitor after bleeding has occurred during treatment with prasugrel or ticagrelor, as soon as re-initiation of antiplatelet therapy is possible. The irreversible binding of prasugrel and the reversible binding of ticagrelor should be taken into consideration when deciding when to restart P2Y 12 inhibitors in these patients. Dose reduction from 10 to 5 mg od prasugrel or from 90 mg to 60 mg bid ticagrelor is not recommended due to lack of evidence of efficacy in patients with a recent ACS. Of note, however, the two doses of ticagrelor provided similarly high levels of platelet inhibition. 46 The bleeding risk is also increased with the thrombin receptor antagonist vorapaxar, 47 having an extremely prolonged half-life. Our consensus is that this drug should be discontinued permanently in patients after bleeding has occurred.
Medically managed patients with acute coronary syndromes
Trials and registries show that a significant proportion of patients with ACS are treated medically without revascularization for various reasons. 48 Such patients on average have worse cardiovascular outcomes compared to those that undergo revascularization. 49 The suggestions for antithrombotic therapy after bleeding, outlined for patients treated invasively, largely apply also to patients receiving medical treatment alone, except for the lack of stent thrombosis risk.
Patients with stabilized coronary artery disease (>12 months after percutaneous coronary intervention or acute coronary syndromes)
Two meta-analyses, based mainly on observational data, suggest that single antiplatelet therapy prescribed for secondary prevention in stable CAD patients should be reinitiated within a few days after bleeding. The first analysis includes 50 279 patients receiving aspirin: cessation of, or non-adherence to, aspirin were associated with a three-fold higher risk of major adverse cardiac events compared to its continued use [OR ¼ 3.14 (1.75-5.61), P ¼ 0.0001]. 50 The risk was magnified in patients with coronary stents. 50 The second metaanalysis evaluated patients with perioperative aspirin interruption. 51 The mean time to coronary events after withholding aspirin was 8.5 days, with events occurring as early as 5 days after withdrawal. On the other hand, a large randomized trial (POISE-2), 52 comparing perioperative aspirin vs. placebo among patients considered at risk of cardiovascular events and undergoing non-cardiac surgery, showed no significant effect of aspirin on the 30-day rate of death or non-fatal myocardial infarction but an increased risk of major bleeding vs. placebo. Of note, less than one third of the POISE-2 population had prior vascular disease and only 23% had CAD.
Resuming antiplatelet therapy after gastrointestinal bleeding
The gastrointestinal (GI) tract is one of the most frequent bleeding sources in patients with CAD. 53 A small randomized controlled trial evaluated the effect of early resumption of aspirin, 80 mg daily, compared to placebo among 156 patients presenting with peptic ulcer bleeding while on aspirin. 54 
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In patients with high-risk peptic ulcer (Forrest Ia, Ib, IIa, IIb), early reintroduction of aspirin by day 3 was recommended, provided that adequate haemostasis had been established ( Figure 2) . 55 In patients on DAPT, it was recommended to continue DAPT without interruption if endoscopy showed low-risk stigmata. With high-risk stigmata, restarting single treatment with low-dose aspirin was recommended, followed by early consultation with a cardiologist for recommendation on resumption of the second antiplatelet agent. Since high-dose proton pump inhibitor (PPI) is recommended in all patients with bleeding peptic ulcer, 55,56 a rapid healing of the lesion is expected. A repeat endoscopy after the bleeding event might help to assure the safety of introducing clopidogrel in addition to aspirin.
Consensus summary on antiplatelet therapy after extracranial bleed iii. In patients with bleeding after BVS implantation, DAPT may be necessary up to 12 months after implantation. iv. Clopidogrel, as less effective but also with a tendency for less bleeding rates, may be used as P2Y 12 inhibitor of choice after bleeding has occurred on prasugrel or ticagrelor. The duration of the effect of prasugrel (7-10 days) or ticagrelor (3-5 days) 32 should be taken into consideration when deciding when to restart P2Y 12 inhibitors in these patients. v. In patients who develop major bleeding under vorapaxar, we suggest permanent discontinuation of the latter. vi. In medically managed ACS patients who develop major bleeding on DAPT, single antiplatelet therapy may be considered, given the lack of stent thrombosis risk. vii. For patients with stable CAD or ACS who develop upper GI (non-variceal) bleeding, antiplatelet therapy (single or dual) can be continued without interruption if endoscopy identifies low-risk bleeding stigmata ( Figure 2) . If high-risk bleeding stigmata are identified and bleeding has been controlled by interventional endoscopy, aspirin can be restarted within 3 days. 55 If high-risk stigmata are identified in patients on DAPT,
resuming the second antiplatelet agent should be on an individual basis after careful weighing potential thrombotic and bleeding risks. viii. Addition of a PPI is recommended in all cases of upper GI bleeding. 55 ,56 PPI should also be used in patients on DAPT at higher than average risk of GI bleeds. 32 The pharmacodynamic interaction between PPIs (especially omeprazole) and clopidogrel has not so far been clearly associated with worse clinical outcome, but it is preferred to use PPIs with weaker CYP2C19 inhibition (e.g. pantoprazole). 56 
Oral anticoagulant therapy after extracranial bleeding
Treatment with OACs reduces the risk of stroke and systemic embolism in patients with AF. Cessation of OACs has been shown to be associated with an increased risk of stroke even after short interruptions.
57,58
Vitamin K-antagonists (VKA)
A recent meta-analysis of studies in patients on long-term VKA demonstrated that resumption of warfarin following interruption due to GI bleeding was associated with a reduction in thromboembolic events and mortality without any significant increase in recurrent GI bleeding. 59 In a retrospective study of patients with non-valvular AF, restarting warfarin after major GI bleeding was independently associated with decreased mortality as compared to permanent warfarin cessation. 60 No significant difference in the incidence of new GI bleeding was found when warfarin was resumed after 1 week vs. 1 month; however, when warfarin was restarted before the 1st week after GI bleeding had passed, the risk of recurrent bleeding was significantly enhanced. Based on these data, in the presence of a clear indication, VKA therapy should be resumed within 1 week following major GI bleeding.
60-62
Figure 2 Algorithm for the management of patients with upper gastrointestinal haemorrhage who are using antiplatelet agent(s); modified with permission from Gralnek et al.
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APT, antiplatelet therapy; ASA, aspirin; DAPT, dual antiplatelet therapy; GI, gastrointestinal.
In patients with mechanical heart valves, discontinuation of VKA is associated with a high risk of thrombosis and is generally discouraged.
Non-vitamin K antagonist oral anticoagulants (NOAC)
The NOACs have not been tested in AF patients with recent bleeds and the optimal time for restarting NOAC after bleeding is unknown. In a recent study with the antidote idarucizumab for patients on dabigatran presenting a life-threatening bleed or requiring urgent surgery, thrombotic events occurred within 6 days after idarucizumab administration when anticoagulation was not reinitiated. 17 It may be reasonable to follow the same advice as for VKA, being aware that the full anticoagulant effect of NOAC occurs sooner (within 1-4 h) 63 than with VKA (several days). When (re)starting a NOAC, renal function should be carefully assessed and monitored to avoid drug accumulation. The recommended time interval during follow-up for monitoring of renal function depends on the level of renal function: If creatinine clearance (CrCl) is less than 60 mL/min, then recheck renal function every x months, where x ¼ CrCl/10. 63 After major bleeding, however, this interval should be reduced. Some of the NOACs are associated with an increased risk of GI bleeding compared to warfarin. 16, 64 Switching to warfarin or to a NOAC without an increased risk of GI bleeding compared to warfarin (e.g. apixaban) 16 ,64 may be considered.
Consensus summary on anticoagulant therapy after extracranial bleed i. After extracranial bleeding, OAC should be reinitiated as soon as the cardiovascular thrombotic risks associated with discontinuation are thought to outweigh the risk of re-bleeding with reinitiation, in most cases within 1 week. ii. When (re)starting a NOAC, renal function should be carefully assessed and monitored to avoid drug accumulation. iii. If an antidote (idaruzicumab) has been used to reverse the anticoagulant effect of a NOAC, it is suggested to restart OAC as soon as possible, preferably within 3-4 days if the individual bleeding risk allows. iv. In patients with mechanical heart valves, discontinuation of VKA is associated with a high risk of thrombosis and is discouraged, particularly for valves in the mitral position. NOACs are currently contraindicated for patients with mechanical heart valves.
Resuming antithrombotic therapy in patients with an indication for both antiplatelets and oral anticoagulant
A particular challenge in terms of antithrombotic treatment is patients who present with both AF and ACS/coronary stenting, most of them having an indication for both DAPT and OAC. A period of triple therapy is recommended in most patients, followed by double therapy (OAC plus single antiplatelet) up to one year; thereafter OAC alone is considered sufficient. 32, 63 Combining DAPT with OAC (VKA or NOAC) significantly increases bleeding risk, 65 regardless of any of the large variety of possible combinations. The What is the Optimal antiplatElet and anticoagulant therapy in patients with OAC and coronary StenTing (WOEST) pilot trial of 573 patients demonstrated that double therapy (VKA plus clopidogrel) was safer with respect to BARC bleeding compared to triple therapy (VKA plus clopidogrel and aspirin), 66 and registries have shown similar findings. 65, 67 The recent Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation (ISAR TRIPLE) study enrolled 614 patients receiving VKA who underwent DES implantation and showed that outcomes were similar if clopidogrel, on top of VKA and aspirin, was administered for 6 weeks or 6 months. 68 Both these trials were too small to reliably assess ischaemic outcomes, and the patients were stable and had not suffered a bleed. Nevertheless, as an extrapolation from these studies, we suggest stopping either aspirin or clopidogrel when a patient develops major bleeding during triple oral antithrombotic therapy. In patients who develop major bleeding on double therapy (OAC plus single antiplatelet), discontinuation of the antiplatelet agent may be considered before 1 year has passed, as long as the athero-thrombotic risk is moderate or less ( Table 1) . 63 There is yet no randomized study comparing VKA vs. NOAC in the setting of AF with ACS/PCI, and the guidelines suggest that either can be used in combination with antiplatelet therapy. 32 With respect to choice of antiplatelet therapy, the ESC guidelines recommend avoiding the use of prasugrel or ticagrelor as part of triple therapy. 32 The use of ticagrelor in combination with a NOAC is currently being tested in prospective randomized trials (NCT02164864, NCT02415400). When NOACs are combined with antiplatelet drugs, the lowest effective dose for stroke prevention should be used, meaning dabigatran 110 mg bid (rivaroxaban 15 mg od, apixaban 2.5 mg bid, or edoxaban 30 mg od, only when criteria for dose lowering are present). 32, 69, 70 The efficacy of rivaroxaban 2.5mg bid has not been demonstrated for stroke prevention in AF patients and cannot be recommended for this indication.
Consensus summary on indication for both antiplatelets and oral anticoagulant after bleeding i. When PCI-treated patients with non-valvular AF develop bleeding during triple oral antithrombotic therapy, we suggest stopping either aspirin or clopidogrel (the latter not within the first month of stenting). For OAC, we suggest a target INR of 2.0-2.5 with VKA and the lowest effective dose for stroke prevention for NOACs. ii. In patients who develop major bleeding on double therapy (OAC plus single antiplatelet), discontinuation of the antiplatelet agent may be considered before 1 year has passed. 63 iii. We suggest DAPT alone (without OAC) for 1 year after ACS/PCI when a patient with non-valvular AF and a low risk of stroke (CHA 2 DS 2 -VASc score 27 1 for men, 2 for women) develops bleeding during triple or double antithrombotic therapy.
Antithrombotic therapy after intracranial haemorrhage Antiplatelet therapy
Approximately 0.2-0.6% of ACS patients develop intracranial haemorrhage (ICH) annually while on antiplatelet therapy. 71 There is limited evidence on whether to stop indefinitely or resume antiplatelet therapy.
Careful consideration of thrombotic and bleeding risk is needed. In general, restarting therapy after temporary discontinuation should be considered if thrombotic risk, as defined in Table 1 , is very high or high. One randomized controlled trial of restarting vs. avoiding antiplatelet drugs after antithrombotic-associated ICH is ongoing (ISRCTN71907627).
Oral anticoagulants
ICH is one of the most feared complications of OAC, occurring in 0.5-1.0% of OAC-treated patients annually. 72 In patients surviving anticoagulation-associated ICH (< 60%), 13 the question is whether to restart OAC. A systematic review of observational studies of patients with prosthetic heart valves developing an ICH concluded that, in patients with mechanical heart valves, anticoagulation with heparin can safely be restarted as early as 3 days after ICH and switched to VKA at 7 days without major concerns of bleeding. 73 For patients without mechanical valves, the dilemma is whether to (re)start OAC at all after ICH. [74] [75] [76] [77] Despite summaries of product characteristics stating that ICH constitutes a contraindication to OAC, several observational studies have compared (re)starting vs. avoiding OAC after ICH. 61, 76, [78] [79] [80] The three most informative studies included adults with various types of ICH and a variety of indications for OAC (mainly AF), and quantified the risks of recurrent ICH or ischaemic events for patients who avoided or restarted warfarin. 61, 76, 78 Data from these studies suggest a reduction in ischaemic events, in recurrent ICH and in death rates associated with restarting warfarin, although confounding by indication is likely, given the nonrandomized designs. 61, 76, 78 The thromboembolic potential of the underlying condition demanding OAC, as stratified in Table 1 , the site of the ICH, the presence of brain microbleeds on magnetic resonance imaging, and the patient's general bleeding risk ( Table 2 ) should all be considered (Figure 3) . 74, 75 Recurrent ICH is more common with cortical ICH, multiple lobar microbleeds, family history of ICH, amyloid angiopathy, and lack of reversible/precipitating factors. Reversible or treatable causes of ICH, or the urgent need for anticoagulation in patients with a mechanical valve (Figure 3) , favour restarting, whereas recent PCI and need for DAPT favour temporary discontinuation of anticoagulation. If the decision is to restart anticoagulation, the optimal timing of resumption is uncertain: 16, 73, 75, 76, 81 the guidelines of the major American societies suggest to avoid OAC for at least 4 weeks after ICH in patients without mechanical heart valves. 81 All of the existing evidence involves VKAs. The NOACs appear promising because of the lower risks of ICH than warfarin in trials of patients with non-valvular AF, but these drugs have not been tested in patients with prior ICH. All NOACs are currently contraindicated in the presence of mechanical heart valves given the negative results of the Dabigatran Etexilate in Patients with Mechanical Heart Valves (RE-ALIGN) trial. 82 In AF patients with lobar ICH and/or multiple lobar microbleeds and/or CHA 2 DS 2 -VASc score 4, left atrial appendage occlusion is an option. 83, 84 One randomized trial of apixaban vs. no anticoagulation after anticoagulation-associated ICH is ongoing (NTR4526).
Consensus summary on oral anticoagulant after intracranial haemorrhage
i. Whether and when to restart OAC after an ICH should be decided on an individual basis, depending on the patient s thrombotic risk and the risk of recurrent bleeding ( Figure 3) . Close collaboration between neurologists and cardiologists is needed to make individualized decisions. ii. In the absence of mechanical valves, NOACs may be preferable to warfarin after ICH, given their lower incidence of ICH among nonvalvular AF patients in phase III trials, but their efficacy and safety have still to be established in this setting. If one of the NOACs is chosen, the lowest effective dose for stroke prevention in AF should be preferred. Renal function, body weight, age, and drug interactions should be carefully considered to avoid drug-overdosing.
The future Need for randomized evidence
There is a shortage of observational data, and even more so of randomized trials, describing the risks and benefits of when and how to resume antithrombotic drugs after bleeding in patients with CAD and/or AF. Current antithrombotic management is largely derived from randomized trials conducted in patients without a history of bleeding. Although the benefits observed in these trials are likely to apply also to patients who have a history of bleeding, the trade-off between the absolute reduction in thrombotic events and any absolute increase in recurrent bleeding events, as well as the net functional consequences for the patient, remain to be determined. The results of ongoing trials for this important group of patients are eagerly awaited.
Conclusion
The increasing use of potent antithrombotic drugs and drug combinations raises challenges for clinicians managing patients who develop 
